Chronic rhinosinusitis pathogenesis - 04/12/15
, Noam A. Cohen, MD, PhD b, e, f, ‡Abstract |
There are a variety of medical conditions associated with chronic sinonasal inflammation, including chronic rhinosinusitis (CRS) and cystic fibrosis. In particular, CRS can be divided into 2 major subgroups based on whether nasal polyps are present or absent. Unfortunately, clinical treatment strategies for patients with chronic sinonasal inflammation are limited, in part because the underlying mechanisms contributing to disease pathology are heterogeneous and not entirely known. It is hypothesized that alterations in mucociliary clearance, abnormalities in the sinonasal epithelial cell barrier, and tissue remodeling all contribute to the chronic inflammatory and tissue-deforming processes characteristic of CRS. Additionally, the host innate and adaptive immune responses are also significantly activated and might be involved in pathogenesis. Recent advancements in the understanding of CRS pathogenesis are highlighted in this review, with special focus placed on the roles of epithelial cells and the host immune response in patients with cystic fibrosis, CRS without nasal polyps, or CRS with nasal polyps.
Le texte complet de cet article est disponible en PDF.Key words : Chronic rhinosinusitis, nasal polyps, mucociliary clearance, epithelial cells, inflammation, microbiome
Abbreviations used : ASL, CF, CFTR, CRS, CRSsNP, CRSwNP, MCC, NO, NOS, PAMP, T2R, Treg, UT
Plan
| Series editors: Joshua A. Boyce, MD, Fred Finkelman, MD, and William T. Shearer, MD, PhD |
|
| Some of the research described in this review and effort directed towards writing the review was supported by USPHS grants R01DC013588, R21DC013886 (to N.A.C.), and R03DC013862 (to R.J.L.); National Institutes of Health grants T32 AI083216 and R01 AI104733 (to R.P.S.); the Ernest S. Bazley Foundation (to R.P.S.); the Chronic Rhinosinusitis Integrative Studies Program U19-AI106683 (to R.P.S.), and a philanthropic contribution from the RLG Foundation (to N.A.C.). |
|
| Disclosure of potential conflict of interest: R. J. Lee has received a grant from the National Institutes of Health (NIH). R. P. Schleimer has received grants from the NIH; has consultant arrangements with Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Merck, BioMarck, and Sanofi; and has stock/stock options with Allakos, Aurasense, and BioMarck. The rest of the authors declare that they have no relevant conflicts of interest. |
|
| Terms in boldface and italics are defined in the glossary on page 1443. |
Vol 136 - N° 6
P. 1442-1453 - décembre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
